BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32839150)

  • 1. Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?
    Austin RM; Onisko A; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):602-606. PubMed ID: 32839150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.
    Gustavsson I; Aarnio R; Berggrund M; Hedlund-Lindberg J; Strand AS; Sanner K; Wikström I; Enroth S; Olovsson M; Gyllensten U
    Br J Cancer; 2018 Mar; 118(6):896-904. PubMed ID: 29438367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that supports policies to delay cervical screening until after age 25 years.
    Dickinson JA; Ogilvie G; Van Niekerk D; Popadiuk C
    CMAJ; 2017 Mar; 189(10):E380-E381. PubMed ID: 28385818
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary high-risk HPV screening for cervical cancer in post-menopausal women.
    Gyllensten U; Gustavsson I; Lindell M; Wilander E
    Gynecol Oncol; 2012 May; 125(2):343-5. PubMed ID: 22293044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and carcinogenic risk of high-risk human papillomavirus subtypes in different cervical cytology: a study of 124,251 cases from the largest academic center in China.
    Tao X; Zhang H; Wang S; Chen T; Cong Q; Wang L; Zhou X; Zhao C
    J Am Soc Cytopathol; 2021; 10(4):391-398. PubMed ID: 33906830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study points to value of HPV screening for cervical cancer: test may be viable alternative to Pap test.
    Printz C
    Cancer; 2014 Dec; 120(23):3589-90. PubMed ID: 25410486
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of several screening approaches for detection of cervical lesions in rural Shandong, China.
    Zong LJ; Zhang YZ; Yang XS; Jiang J; Cui BX; Qiao YB; Li L; Jiang K; Zhang WJ; Kong BH; Shen K
    Asian Pac J Cancer Prev; 2015; 16(5):1907-12. PubMed ID: 25773843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer screening and updated Pap guidelines.
    Warren JB; Gullett H; King VJ
    Prim Care; 2009 Mar; 36(1):131-49, ix. PubMed ID: 19231606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
    Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel.
    Gustavsson I; Aarnio R; Berggrund M; Hedlund-Lindberg J; Sanner K; Wikström I; Enroth S; Olovsson M; Gyllensten U
    Int J Cancer; 2019 Jan; 144(1):89-97. PubMed ID: 29943822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.
    Gage JC; Katki HA; Schiffman M; Fetterman B; Poitras NE; Lorey T; Cheung LC; Castle PE; Kinney WK
    Int J Cancer; 2015 Apr; 136(7):1665-71. PubMed ID: 25136967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
    Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
    Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.